GSK’s lat­est pipeline re­view in­cludes a slate of COPD pro­grams head­ed to the scrap heap

Glax­o­SmithK­line R&D chief Hal Bar­ron has tossed a line­up of COPD drugs out of the pipeline in the lat­est shift away from res­pi­ra­to­ry dis­eases. And there was a can­cer drug as well as an HIV pro­gram in the mix of the nixed.

Bar­ron was quick to high­light his fo­cus on on­col­o­gy af­ter he took the reins at GSK’s big R&D group, ex­pect­ing to scale down in res­pi­ra­to­ry, where GSK has had some suc­cess­es and many set­backs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER